Balchem Q2 2026 Earnings: All Three Segments Drive 11.2% Sales Growth

Balchem (NASDAQ: BCPC) reported fiscal Q2 2026 net sales of $284.0 million, up 11.2% year over year, while diluted GAAP EPS increased to $1.39 from $1.17. For the quarter ended June 30, 2026, net earnings grew faster than revenue as all three reporting segments increased sales and operating earnings, although free cash flow declined from the prior-year period.

Core financial results

Sales growth was broad-based, with Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products all contributing. GAAP gross profit rose 11.4%, while gross margin edged up 10 basis points as sales growth and manufacturing efficiencies slightly outweighed higher manufacturing input costs.

Operating expenses increased by about 6.7% to $44.5 million, primarily because of higher compensation-related costs. Because expenses grew more slowly than revenue, operating income advanced approximately 15.1% and net earnings rose 16.6%.

Adjusted EBITDA and adjusted EPS are non-GAAP measures. Free cash flow is also a non-GAAP measure defined by Balchem as operating cash flow less capital expenditures, net of proceeds from asset sales.

Business and segment performance

Human Nutrition and Health remained Balchem’s largest segment, while Animal Nutrition and Health recorded the fastest sales and operating earnings growth. Specialty Products also increased sales and earnings, supported by both of its main businesses.

Human Nutrition and Health benefited from higher sales in both nutrients and food ingredients and solutions. Favorable product mix supported profitability, but higher manufacturing input costs and operating expenses limited the benefit.

Animal Nutrition and Health grew through higher sales in both monogastric and ruminant markets. Its operating earnings increased substantially faster than sales, indicating improved operating leverage despite higher input costs and expenses.

Specialty Products was supported by higher sales in performance gases and plant nutrition. Higher volume and favorable mix more than offset manufacturing and operating cost pressures.

Operating leverage, rather than margin expansion, drove earnings growth

Balchem’s gross margin was nearly unchanged at 36.5%, so faster earnings growth did not come from a major improvement in production-level profitability. Instead, operating expenses rose more slowly than sales, lifting the GAAP operating margin to approximately 20.9% from 20.1%.

Lower financing costs provided an additional benefit. Net interest expense decreased to $1.9 million from $2.8 million because of lower outstanding borrowings and lower interest rates. This was partly offset by an increase in the effective tax rate to 22.8% from 21.9%, reflecting lower tax benefits from stock-based compensation.

Cash flow, balance sheet, and capital allocation

Cash generation did not keep pace with earnings growth during the quarter. Operating cash flow was nearly flat at $46.7 million, while free cash flow declined to $36.2 million because capital expenditures net of asset-sale proceeds increased to $10.5 million from $6.6 million.

Balchem used $28.8 million to repurchase common stock during the quarter, paid $27.8 million in income taxes, and made $17.0 million of net debt payments. At June 30, the company held $63.2 million of cash against $152.0 million outstanding on its revolving loan, resulting in net debt of $88.8 million and a net leverage ratio of 0.3 times trailing adjusted EBITDA.

Inventory increased to $161.6 million from $131.4 million at December 31, 2025, while cash declined from $74.6 million. After the quarter, Balchem amended its revolving credit facility on July 24, increasing available borrowing capacity from $550 million to $650 million and extending the maturity from July 2027 to July 2031.

Risks investors need to monitor

• Manufacturing cost pressure: All three reporting segments cited higher manufacturing input costs as a partial offset to sales growth, making cost control important to future margin performance.
• Higher operating expenses: Compensation-related costs drove quarterly operating expenses higher, and continued expense growth could reduce operating leverage.
• Weaker free cash flow conversion: Free cash flow declined despite higher net earnings because capital spending increased. A sustained divergence would limit internally generated funds available for debt reduction and capital allocation.
• Inventory growth: Inventory rose by approximately $30.1 million from year-end, tying up additional capital and making working-capital conversion an area to watch.
• Higher effective tax rate: Reduced stock-based compensation tax benefits raised the quarterly tax rate, partially offsetting improvements in operating income and interest expense.

Summary

Balchem’s fiscal Q2 2026 results reflected broad sales growth across all three segments, with Animal Nutrition and Health producing the strongest earnings increase. Stable gross margin, slower expense growth, and lower interest costs allowed net earnings to outpace revenue. The main follow-up areas are manufacturing costs, compensation expenses, inventory levels, and whether free cash flow returns to growth as capital spending changes.